Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial. (Q44212082)
Jump to navigation
Jump to search
scientific article published in October 2002
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial. |
scientific article published in October 2002 |
Statements
Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial (English)
Jean-Marc Nabholtz
Jacques Cantin
Jose Chang
Raymond Guevin
Ravi Patel
Katherine Tkaczuk
Pavel Vodvarka
Mary-Ann Lindsay
David Reese
Alessandro Riva